Alembic Pharmaceuticals Ltd
NSE: APLLTD BSE: 533573
₹793.80
(0.86%)
Sun, 17 May 2026, 11:45 am
Market Cap154.38B
PE Ratio24.81
Dividend1.40
Health Technology
Pharmaceuticals: Major
24.5KAlembic Pharmaceuticals Analysis
dividend
- Dividends paid are well covered by earnings (6.3x coverage).
- Dividends after 3 years are expected to be well covered by earnings (4.4x coverage).
- Alembic Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividend payments have increased, but Alembic Pharmaceuticals only paid a dividend in the past 8 years.
- Whilst dividend payments have been stable, Alembic Pharmaceuticals has been paying a dividend for less than 10 years.
- Alembic Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Alembic Pharmaceuticals is expected to increase by more than 50% in 2 years time.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- Alembic Pharmaceuticals's revenue growth is expected to exceed the India market average.
- Alembic Pharmaceuticals's earnings are expected to grow by 0.5% yearly, however this is not considered high growth (20% yearly).
- Alembic Pharmaceuticals's earnings growth is positive but not above the India market average.
- Alembic Pharmaceuticals's earnings growth is positive but not above the low risk savings rate of 7.2%.
- Alembic Pharmaceuticals's earnings are expected to decrease over the next year.
- Alembic Pharmaceuticals's earnings are expected to increase but not above the low risk growth rate in 3 years time
- Alembic Pharmaceuticals's net income is expected to increase but not above the 50% threshold in 2 years time.
- Alembic Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- A decline in Alembic Pharmaceuticals's performance (ROE) is expected over the next 3 years.
- Alembic Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Alembic Pharmaceuticals's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
health
- Alembic Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Alembic Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Alembic Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (25.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.4x debt.
- Alembic Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 43.7x coverage).
- The level of debt compared to net worth has increased over the past 5 years (29.8% vs 54.8% today).
- Alembic Pharmaceuticals's level of debt (54.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Alembic Pharmaceuticals board of directors is about average.
- Chirayu's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Alembic Pharmaceuticals management team is about average.
- Chirayu's remuneration is higher than average for companies of similar size in India.
misc
- Alembic Pharmaceuticals has significant price volatility in the past 3 months.
past
- Alembic Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (41.7% vs 8.1%)
- Alembic Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- Alembic Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Alembic Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Alembic Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (41.7% vs 22.7%).
- Alembic Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
value
- APLLTD outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- APLLTD outperformed the Market in India which returned -14.5% over the past year.
- Alembic Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Alembic Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Alembic Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Alembic Pharmaceuticals is poor value based on expected growth next year.
- Alembic Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Alembic Pharmaceuticals is overvalued based on earnings compared to the India market.
- NSEI:APLLTD is up 4% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:APLLTD is up 4% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800